세계의 주사 치료 시장(2024-2028년)

The rosacea treatment market is forecasted to grow by USD 744.29 mn during 2023-2028, accelerating at a CAGR of 6.2% during the forecast period. The report on the rosacea treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing focus on personalized treatment approaches, growing awareness of rosacea leading to better diagnosis, and rising number of strategies undertaken by market vendors.

Technavio's rosacea treatment market is segmented as below:

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Route Of Administration

• Topical
• Oral
• Injectable

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the rising demand for cosmetic procedures as one of the prime reasons driving the rosacea treatment market growth during the next few years. Also, rising focus on combination therapies and increasing demand for natural and gentle treatments will lead to sizable demand in the market.

The report on the rosacea treatment market covers the following areas:

• Rosacea treatment market sizing
• Rosacea treatment market forecast
• Rosacea treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading rosacea treatment market vendors that include AbbVie Inc., Aclaris Therapeutics Inc., AKUMS, Bausch Health Companies Inc., Croda International Plc, Dermata Therapeutics Inc., Galderma SA, Glenmark Pharmaceuticals Ltd., Hovione, Journey Medical Corp., LEO Pharma AS, Lupin Ltd., Maruho Co. Ltd., Mayne Pharma Group Ltd., Pfizer Inc., PruGen LLC, Sol-Gel Technologies Ltd., Taro Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Zydus Lifesciences Ltd.. Also, the rosacea treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Route of Administration
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global rosacea treatment market 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global rosacea treatment market 2018 - 2022 ($ million)
• 4.2 Distribution Channel Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
• 4.3 Route of Administration Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Distribution Channel

• 6.1 Market segments
• Exhibit 30: Chart on Distribution Channel - Market share 2023-2028 (%)
• Exhibit 31: Data Table on Distribution Channel - Market share 2023-2028 (%)
• 6.2 Comparison by Distribution Channel
• Exhibit 32: Chart on Comparison by Distribution Channel
• Exhibit 33: Data Table on Comparison by Distribution Channel
• 6.3 Hospital pharmacies - Market size and forecast 2023-2028
• Exhibit 34: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 35: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 36: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
• 6.4 Retail pharmacies - Market size and forecast 2023-2028
• Exhibit 38: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 39: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 40: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
• 6.5 Online pharmacies - Market size and forecast 2023-2028
• Exhibit 42: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 43: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 44: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibit 45: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
• 6.6 Market opportunity by Distribution Channel
• Exhibit 46: Market opportunity by Distribution Channel ($ million)
• Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ million)

7 Market Segmentation by Route of Administration

• 7.1 Market segments
• Exhibit 48: Chart on Route of Administration - Market share 2023-2028 (%)
• Exhibit 49: Data Table on Route of Administration - Market share 2023-2028 (%)
• 7.2 Comparison by Route of Administration
• Exhibit 50: Chart on Comparison by Route of Administration
• Exhibit 51: Data Table on Comparison by Route of Administration
• 7.3 Topical - Market size and forecast 2023-2028
• Exhibit 52: Chart on Topical - Market size and forecast 2023-2028 ($ million)
• Exhibit 53: Data Table on Topical - Market size and forecast 2023-2028 ($ million)
• Exhibit 54: Chart on Topical - Year-over-year growth 2023-2028 (%)
• Exhibit 55: Data Table on Topical - Year-over-year growth 2023-2028 (%)
• 7.4 Oral - Market size and forecast 2023-2028
• Exhibit 56: Chart on Oral - Market size and forecast 2023-2028 ($ million)
• Exhibit 57: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
• Exhibit 58: Chart on Oral - Year-over-year growth 2023-2028 (%)
• Exhibit 59: Data Table on Oral - Year-over-year growth 2023-2028 (%)
• 7.5 Injectable - Market size and forecast 2023-2028
• Exhibit 60: Chart on Injectable - Market size and forecast 2023-2028 ($ million)
• Exhibit 61: Data Table on Injectable - Market size and forecast 2023-2028 ($ million)
• Exhibit 62: Chart on Injectable - Year-over-year growth 2023-2028 (%)
• Exhibit 63: Data Table on Injectable - Year-over-year growth 2023-2028 (%)
• 7.6 Market opportunity by Route of Administration
• Exhibit 64: Market opportunity by Route of Administration ($ million)
• Exhibit 65: Data Table on Market opportunity by Route of Administration ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 67: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibit 68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 69: Chart on Geographic comparison
• Exhibit 70: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
• Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
• Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
• Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 Germany - Market size and forecast 2023-2028
• Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.9 China - Market size and forecast 2023-2028
• Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
• 9.10 UK - Market size and forecast 2023-2028
• Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.11 Russia - Market size and forecast 2023-2028
• Exhibit 103: Chart on Russia - Market size and forecast 2023-2028 ($ million)
• Exhibit 104: Data Table on Russia - Market size and forecast 2023-2028 ($ million)
• Exhibit 105: Chart on Russia - Year-over-year growth 2023-2028 (%)
• Exhibit 106: Data Table on Russia - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 107: Market opportunity By Geographical Landscape ($ million)
• Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 109: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 111: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 112: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 113: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 114: Matrix on vendor position and classification
• 12.3 Aclaris Therapeutics Inc.
• Exhibit 115: Aclaris Therapeutics Inc. - Overview
• Exhibit 116: Aclaris Therapeutics Inc. - Business segments
• Exhibit 117: Aclaris Therapeutics Inc. - Key news
• Exhibit 118: Aclaris Therapeutics Inc. - Key offerings
• Exhibit 119: Aclaris Therapeutics Inc. - Segment focus
• 12.4 Bausch Health Companies Inc.
• Exhibit 120: Bausch Health Companies Inc. - Overview
• Exhibit 121: Bausch Health Companies Inc. - Business segments
• Exhibit 122: Bausch Health Companies Inc. - Key news
• Exhibit 123: Bausch Health Companies Inc. - Key offerings
• Exhibit 124: Bausch Health Companies Inc. - Segment focus
• 12.5 Croda International Plc
• Exhibit 125: Croda International Plc - Overview
• Exhibit 126: Croda International Plc - Business segments
• Exhibit 127: Croda International Plc - Key news
• Exhibit 128: Croda International Plc - Key offerings
• Exhibit 129: Croda International Plc - Segment focus
• 12.6 Galderma SA
• Exhibit 130: Galderma SA - Overview
• Exhibit 131: Galderma SA - Product / Service
• Exhibit 132: Galderma SA - Key news
• Exhibit 133: Galderma SA - Key offerings
• 12.7 Glenmark Pharmaceuticals Ltd.
• Exhibit 134: Glenmark Pharmaceuticals Ltd. - Overview
• Exhibit 135: Glenmark Pharmaceuticals Ltd. - Product / Service
• Exhibit 136: Glenmark Pharmaceuticals Ltd. - Key offerings
• 12.8 Journey Medical Corp.
• Exhibit 137: Journey Medical Corp. - Overview
• Exhibit 138: Journey Medical Corp. - Product / Service
• Exhibit 139: Journey Medical Corp. - Key offerings
• 12.9 LEO Pharma AS
• Exhibit 140: LEO Pharma AS - Overview
• Exhibit 141: LEO Pharma AS - Business segments
• Exhibit 142: LEO Pharma AS - Key offerings
• Exhibit 143: LEO Pharma AS - Segment focus
• 12.10 Lupin Ltd.
• Exhibit 144: Lupin Ltd. - Overview
• Exhibit 145: Lupin Ltd. - Product / Service
• Exhibit 146: Lupin Ltd. - Key news
• Exhibit 147: Lupin Ltd. - Key offerings
• 12.11 Maruho Co. Ltd.
• Exhibit 148: Maruho Co. Ltd. - Overview
• Exhibit 149: Maruho Co. Ltd. - Product / Service
• Exhibit 150: Maruho Co. Ltd. - Key offerings
• 12.12 Mayne Pharma Group Ltd.
• Exhibit 151: Mayne Pharma Group Ltd. - Overview
• Exhibit 152: Mayne Pharma Group Ltd. - Business segments
• Exhibit 153: Mayne Pharma Group Ltd. - Key news
• Exhibit 154: Mayne Pharma Group Ltd. - Key offerings
• Exhibit 155: Mayne Pharma Group Ltd. - Segment focus
• 12.13 Pfizer Inc.
• Exhibit 156: Pfizer Inc. - Overview
• Exhibit 157: Pfizer Inc. - Product / Service
• Exhibit 158: Pfizer Inc. - Key news
• Exhibit 159: Pfizer Inc. - Key offerings
• 12.14 Sol-Gel Technologies Ltd.
• Exhibit 160: Sol-Gel Technologies Ltd. - Overview
• Exhibit 161: Sol-Gel Technologies Ltd. - Product / Service
• Exhibit 162: Sol-Gel Technologies Ltd. - Key offerings
• 12.15 Taro Pharmaceutical Industries Ltd.
• Exhibit 163: Taro Pharmaceutical Industries Ltd. - Overview
• Exhibit 164: Taro Pharmaceutical Industries Ltd. - Product / Service
• Exhibit 165: Taro Pharmaceutical Industries Ltd. - Key offerings
• 12.16 Teva Pharmaceutical Industries Ltd.
• Exhibit 166: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 167: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 168: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 169: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 170: Teva Pharmaceutical Industries Ltd. - Segment focus
• 12.17 Zydus Lifesciences Ltd.
• Exhibit 171: Zydus Lifesciences Ltd. - Overview
• Exhibit 172: Zydus Lifesciences Ltd. - Business segments
• Exhibit 173: Zydus Lifesciences Ltd. - Key offerings
• Exhibit 174: Zydus Lifesciences Ltd. - Segment focus

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 175: Inclusions checklist
• Exhibit 176: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 177: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 178: Research methodology
• Exhibit 179: Validation techniques employed for market sizing
• Exhibit 180: Information sources
• 13.5 List of abbreviations
• Exhibit 181: List of abbreviations